CN112955438A - 蛋白质酪氨酸磷酸酶抑制剂和其使用方法 - Google Patents

蛋白质酪氨酸磷酸酶抑制剂和其使用方法 Download PDF

Info

Publication number
CN112955438A
CN112955438A CN201980054332.9A CN201980054332A CN112955438A CN 112955438 A CN112955438 A CN 112955438A CN 201980054332 A CN201980054332 A CN 201980054332A CN 112955438 A CN112955438 A CN 112955438A
Authority
CN
China
Prior art keywords
fluoro
trione
thiadiazolidine
lambda
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980054332.9A
Other languages
English (en)
Chinese (zh)
Inventor
E·法尼
R·K·希鲁迪
Z·熊
Q·I·张
M·奥康纳
G·哈尔沃森
H·赵
C·鲍姆加特纳
J·M·弗罗斯特
P·凯姆
J·R·艾伯特
A·博格丹
C·埃科诺莫
王学庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Calico Life Sciences LLC
Original Assignee
AbbVie Inc
Calico Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc, Calico Life Sciences LLC filed Critical AbbVie Inc
Publication of CN112955438A publication Critical patent/CN112955438A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201980054332.9A 2018-06-21 2019-06-21 蛋白质酪氨酸磷酸酶抑制剂和其使用方法 Pending CN112955438A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688226P 2018-06-21 2018-06-21
US62/688226 2018-06-21
PCT/US2019/038459 WO2019246513A1 (en) 2018-06-21 2019-06-21 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CN112955438A true CN112955438A (zh) 2021-06-11

Family

ID=67254011

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054332.9A Pending CN112955438A (zh) 2018-06-21 2019-06-21 蛋白质酪氨酸磷酸酶抑制剂和其使用方法

Country Status (23)

Country Link
US (1) US10954202B2 (ja)
EP (1) EP3810580A1 (ja)
JP (2) JP7217762B2 (ja)
KR (2) KR102533477B1 (ja)
CN (1) CN112955438A (ja)
AR (1) AR125425A1 (ja)
AU (2) AU2019290197B2 (ja)
BR (1) BR112020026086A2 (ja)
CA (1) CA3104507A1 (ja)
CL (1) CL2020003316A1 (ja)
CO (1) CO2021000447A2 (ja)
CR (1) CR20210017A (ja)
DO (1) DOP2020000252A (ja)
EC (1) ECSP21003520A (ja)
IL (1) IL279587A (ja)
MA (1) MA52963A (ja)
MX (1) MX2020014223A (ja)
PE (1) PE20210372A1 (ja)
PH (1) PH12020552228A1 (ja)
SG (1) SG11202012820PA (ja)
TW (1) TW202016082A (ja)
UY (1) UY38272A (ja)
WO (1) WO2019246513A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115197167A (zh) * 2022-07-22 2022-10-18 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
CN117343052A (zh) * 2023-12-04 2024-01-05 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
CN114025844B (zh) * 2019-03-14 2022-07-26 卡里科生命科学有限责任公司 蛋白酪氨酸磷酸酶抑制剂及其使用方法
AU2020395612A1 (en) * 2019-12-04 2022-06-09 Monash University Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors
EP4077291A1 (en) * 2019-12-18 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
AU2022298654A1 (en) * 2021-06-21 2024-02-01 Abbvie Inc. Degrader compounds and uses thereof
WO2023086495A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
CA3236854A1 (en) * 2021-11-11 2023-05-19 Andrew Bogdan Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024102791A1 (en) * 2022-11-09 2024-05-16 Bristol-Myers Squibb Company Indazol substituted 1,2,5-thiadiazolidin derivatives as inhibitors of protein tyrosine phosphatase (ptpn2) for the treatment of cancer diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082841A1 (en) * 2002-04-03 2003-10-09 Novartis Ag 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
WO2004041799A1 (en) * 2002-11-07 2004-05-21 Astrazeneca Ab 5- (substituted phenyl) -thiadiazolidine-3-ones and their use as ptp1b
WO2007067612A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
IL161582A0 (en) 2001-10-30 2004-09-27 Applied Research Systems Use of oxindole hydrazide derivatives for the preparation of pharmaceutical compositions, certain such new derivatives and their preparation
US20100160228A1 (en) 2007-05-23 2010-06-24 Valtion Teknillinen Tutkimuskeskus Method for inhibiting or stimulating angiogenesis in an individual
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
WO2010118241A2 (en) 2009-04-08 2010-10-14 Indiana University Research & Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
WO2011094806A1 (en) 2010-02-03 2011-08-11 Monash University Diagnostic and prognostic assay for breast cancer
US9828399B2 (en) 2014-02-28 2017-11-28 The Royal Institution For The Advancement Of Learning/Mcgill University TC-PTP inhibitors as APC activators for immunotherapy
AU2015274242A1 (en) 2014-06-10 2016-12-22 Monash University Method of producing leukocytes using PTPN2 inhibition for adoptive cell transfer
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
US20180325925A1 (en) 2015-11-06 2018-11-15 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
US11273166B2 (en) 2017-06-13 2022-03-15 Monash University Methods and compositions for the treatment of obesity
CA3073755A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill Universit Enhancing cd8+ t cells for adoptive cell therapy by inhibiting ptpn1 (ptp1b) and ptpn2 (tc-ptp)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082841A1 (en) * 2002-04-03 2003-10-09 Novartis Ag 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
WO2004041799A1 (en) * 2002-11-07 2004-05-21 Astrazeneca Ab 5- (substituted phenyl) -thiadiazolidine-3-ones and their use as ptp1b
WO2007067612A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115197167A (zh) * 2022-07-22 2022-10-18 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
CN117343052A (zh) * 2023-12-04 2024-01-05 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Also Published As

Publication number Publication date
CR20210017A (es) 2021-11-03
EP3810580A1 (en) 2021-04-28
KR20230074286A (ko) 2023-05-26
WO2019246513A1 (en) 2019-12-26
IL279587A (en) 2021-03-01
AU2019290197B2 (en) 2023-08-24
JP7217762B2 (ja) 2023-02-03
ECSP21003520A (es) 2021-02-26
CL2020003316A1 (es) 2021-06-11
MA52963A (fr) 2021-04-28
PH12020552228A1 (en) 2021-08-16
BR112020026086A2 (pt) 2021-03-23
US10954202B2 (en) 2021-03-23
AU2019290197A1 (en) 2021-01-21
JP2021530443A (ja) 2021-11-11
MX2020014223A (es) 2021-06-23
CA3104507A1 (en) 2019-12-26
US20210009542A1 (en) 2021-01-14
UY38272A (es) 2019-12-31
KR20210034589A (ko) 2021-03-30
PE20210372A1 (es) 2021-02-26
AR125425A1 (es) 2023-07-19
CO2021000447A2 (es) 2021-07-19
KR102533477B1 (ko) 2023-05-18
JP2023055771A (ja) 2023-04-18
SG11202012820PA (en) 2021-01-28
DOP2020000252A (es) 2021-07-15
AU2023263567A1 (en) 2023-11-30
TW202016082A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
CN114025844B (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
CN112955438A (zh) 蛋白质酪氨酸磷酸酶抑制剂和其使用方法
TWI813596B (zh) 整合應激路徑之調節劑
CN112204009A (zh) 整合应激通路的调节剂
CN112105385A (zh) Irak降解剂和其用途
CN113423685A (zh) 整合应激通路的前药调节剂
EP3710456B1 (en) Macrocyclic indole derivatives
WO2016102493A1 (en) Imidazopyridine ezh2 inhibitors
CN116348455A (zh) 蛋白质酪氨酸磷酸酶抑制剂和其使用方法
CN116829555A (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
WO2017025493A1 (en) Quinoline ezh2 inhibitors
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения
TW202120511A (zh) 雜環化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination